# Carnosine protects human microglia against Aβ oligomers through a multimodal mechanism of action: inhibition of oxidative stress, rescue of cellular energy status, and enhancement of phagocytosis

**Authors:** Anna Privitera, Vincenzo Cardaci, Matthew C. Zupan, Lucia Di Pietro, Giuseppe Carota, Jay Sibbitts, Renata Mangione, Andrea Graziani, Lucia Buccarello, Francesco Bellia, Valentina Di Pietro, Giuseppe Lazzarino, Susan M. Lunte, Meredith D. Hartley, Filippo Caraci, Barbara Tavazzi, Emiliano Maiani, Angela M. Amorini, Giacomo Lazzarino, Giuseppe Caruso

PMC · DOI: 10.3389/fimmu.2026.1768094 · Frontiers in Immunology · 2026-02-13

## TL;DR

Carnosine protects brain microglia from damage caused by Alzheimer's-related proteins by reducing stress and boosting cell function.

## Contribution

The study reveals carnosine's multimodal protection of microglia against Aβ oligomers through oxidative stress inhibition, energy rescue, and enhanced phagocytosis.

## Key findings

- Carnosine reduces oxidative and nitrosative stress in microglia exposed to Aβ oligomers.
- Carnosine restores cellular energy metabolism and GSH levels in stressed microglia.
- Carnosine enhances phagocytic activity in human microglial cells.

## Abstract

Carnosine is an endogenous dipeptide composed by β-alanine and L-histidine widely distributed in excitable tissues like muscles and brain. Carnosine participates in the cellular defenses against oxidative/nitrosative stress through a multimodal mechanism of action, including scavenging of the reactive oxygen and nitrogen species (ROS and RNS) and, in brain cells, the inhibition of amyloid-beta (Aβ) aggregation. Microglia play a central role in the pathophysiology of Alzheimer’s disease (AD), maintaining the homeostasis of the brain microenvironment. However, its hyperactivation causes an increased secretion of inflammatory mediators and free radicals, leading to neuroinflammatory phenomena that exacerbate neurodegeneration. In the present work, carnosine was tested for its ability to protect human microglial cells (HMC3) against Aβ oligomers-induced oxidative stress and energy metabolism unbalance.

The effects of carnosine to modulate nitric oxide (NO) and ROS intracellular levels were evaluated by microchip electrophoresis coupled to laser-induced fluorescence (ME-LIF), while additional stress-related parameters and cellular energy metabolism were investigated through high-performance liquid chromatography (HPLC).

Pre-treatment with carnosine counteracted the oxidative/nitrosative stress induced by Aβ1-42 oligomers by decreasing the intracellular levels of NO and ROS, and rescuing GSH levels. Carnosine preserved cellular mitochondrial-related energy metabolism, restoring concentrations of high-energy phosphates, nicotinic coenzymes and oxypurines, and normalizing UDP-derivatives homeostasis. Furthermore, carnosine strongly enhanced the phagocytic activity of HMC3 cells.

These results demonstrate the protective effects of carnosine on human microglial cells against detrimental alterations induced by Aβ oligomers, underlining the multimodal mechanism of action of this dipeptide and supporting its promising potential in the context of AD pathology.

## Linked entities

- **Proteins:** FDI57_gp42 (endonuclease)
- **Chemicals:** carnosine (PubChem CID 439224), nitric oxide (PubChem CID 145068), GSH (PubChem CID 124886)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}, ATD (asphixiating thoracic dystrophy (chondroectodermal dysplasia-like syndrome)) [NCBI Gene 465] {aka ATD1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** amyloid plaques (MESH:D058225), cognitive decline (MESH:D003072), neuronal death (MESH:D009410), attention-deficit/hyperactivity disorder (MESH:D001289), toxicity (MESH:D064420), transient (MESH:C563551), atherosclerosis (MESH:D050197), middle cerebral artery occlusion (MESH:D020244), synaptic loss (MESH:D012183), neurofibrillary tangles (MESH:D055956), cerebral ischemia (MESH:D002545), neuropsychiatric disorders (MESH:D001523), AD (MESH:D000544), schizophrenia (MESH:D012559), Neuroinflammation (MESH:D000090862), inflammation (MESH:D007249), neurodegeneration (MESH:D019636), mitochondrial dysfunction (MESH:D028361), PD (MESH:D010300)
- **Chemicals:** RNS (MESH:D011886), okadaic acid (MESH:D019319), guanosine (MESH:D006151), dopamine (MESH:D004298), UMP (MESH:D014542), NAD+ (MESH:D009243), UTP (MESH:D014544), ROS (MESH:D017382), 6-CFDA (MESH:C093616), hexosamine (MESH:D006595), DMSO (MESH:D004121), glucose (MESH:D005947), polystyrene (MESH:D011137), pyrimidines (MESH:D011743), beta-alanine (MESH:D015091), peroxynitrite (MESH:D030421), CO2 (MESH:D002245), GSH (MESH:D005978), rotenone (MESH:D012402), ATP (MESH:D000255), AMP (MESH:D000249), PDMS (MESH:C013830), 2,2'-azobis(2-amidinopropane) dihydrochloride (MESH:C046728), lipids (MESH:D008055), paraformaldehyde (MESH:C003043), LPS (MESH:D008070), chloroform (MESH:D002725), GMP (MESH:C066524), amino acids (MESH:D000596), MTT (MESH:C070243), Nitrite (MESH:D009573), UDP-Glucose (MESH:D014532), RNS (MESH:D026361), NADP+ (MESH:D009249), MDA (MESH:D008315), amine (MESH:D000588), 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MESH:C022616), UDP-N-acetylglucosamine (MESH:D014537), Car #1-5 (-), superoxide ion (MESH:D013481), penicillin (MESH:D010406), CTP (MESH:D003570), proton (MESH:D011522), probenecid (MESH:D011339), triphosphates (MESH:C005692), glutamate (MESH:D018698), GDP (MESH:D006153), 4-hydroxynonenal (MESH:C027576), SDS (MESH:D012967), UDP (MESH:D014530), dipeptide (MESH:D004151), NO (MESH:D009569), 8-hydroxy-2' -deoxyguanosine (MESH:D000080242), CDP (MESH:D003565), 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (MESH:C503301), ethanol (MESH:D000431), xanthine (MESH:D019820), GlutaMAX (MESH:C054122), purines (MESH:D011687), water (MESH:D014867)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955], Lymnaea stagnalis (great pond snail, species) [taxon 6523], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HMC3 — Homo sapiens (Human), Transformed cell line (CVCL_II76), Abeta1-42 — Homo sapiens (Human), Transformed cell line (CVCL_2561), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946148/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946148/full.md

## References

103 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946148/full.md

---
Source: https://tomesphere.com/paper/PMC12946148